Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Daily

Download Data

Cyteir Therapeutics Inc Earnings Yield on April 12, 2024

Cyteir Therapeutics Inc Earnings Yield is NA on April 12, 2024, a NA change year over year. The earnings yield represents the earnings per share as a percentage of the market price per share. It is calculated by dividing income after tax by the market capitalization. This ratio provides insight into the relative value of a company's earnings in relation to its market value. A higher earnings yield may indicate a relatively undervalued stock.

Cyteir Therapeutics Inc 52-week high Earnings Yield is -16.71% on February 26, 2024, which is NA below the current Earnings Yield.
Cyteir Therapeutics Inc 52-week low Earnings Yield is -66.69% on June 28, 2023, which is NA below the current Earnings Yield.
Cyteir Therapeutics Inc average Earnings Yield for the last 52 weeks is -29.75%.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends